Previous 10 | Next 10 |
BOSTON and LONDON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced ...
Cellular Biomedicine Group (NASDAQ: CBMG ) initiated with Buy rating and $19 (28% upside) price target at BTIG Research. More news on: Cellular Biomedicine Group, Inc., Lexaria Bioscience Corp., Orchard Therapeutics plc, Healthcare stocks news, , Stocks on the move, Read more ...
Orchard Therapeutics (NASDAQ: ORTX ) Chief Commercial Officer Jason Meyenburg will depart to take on a chief executive role in the industry. More news on: Orchard Therapeutics plc, Healthcare stocks news, Read more ...
BOSTON and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, t...
The following slide deck was published by Orchard Therapeutics plc in conjunction with this Read more ...
Orchard Therapeutics (NASDAQ: ORTX ) initiated with Overweight rating at Barclays. More news on: Orchard Therapeutics plc, Idera Pharmaceuticals, Inc., Incyte Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Six of Eight Patients Treated to Date with Follow-up Out to 12 Months in First Patient to Receive Treatment Evidence of Engraftment and Peripheral Blood Alpha-L-iduronidase (IDUA) Enzyme Overexpression Across Cohort BOSTON and LONDON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Orchard Ther...
BOSTON and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced ...
BOSTON and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced t...
Noteworthy events during the week of September 1 - 9 for healthcare investors. More news on: Synlogic, Inc., Orchard Therapeutics plc, Zosano Pharma Corporation, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....